Table 1 Baseline characteristics of 6234 persons born in 1920–1987 who were diagnosed with non-Hodgkin lymphoma in Denmark, 2000–2008, by education
Total | Short education, N =2081 (33%) | Medium education, N =2930 (47%) | Higher education, N =1223 (20%) | |||
|---|---|---|---|---|---|---|
n | (%) | % | % | % | P | |
Sex (n=6234) | ||||||
Men | 3421 | (55) | 47 | 59 | 59 | <0.0001 |
Women | 2813 | (45) | 53 | 41 | 41 | |
Age (years) (n=6234) | ||||||
−49 | 785 | (13) | 5 | 15 | 19 | <0.0001 |
50–59 | 1410 | (23) | 13 | 27 | 29 | |
60–69 | 1824 | (29) | 31 | 29 | 28 | |
70–79 | 1722 | (28) | 39 | 23 | 20 | |
80– | 493 | (8) | 12 | 6 | 5 | |
Cohabiting status (n=6234) | ||||||
Living with partner | 4383 | (70) | 64 | 73 | 75 | <0.0001 |
Single | 1851 | (30) | 36 | 27 | 25 | |
Disposable income (n=6234) | ||||||
Lowest | 1509 | (24) | 41 | 20 | 7 | <0.0001 |
Second quartile | 1557 | (25) | 30 | 26 | 14 | |
Third quartile | 1573 | (25) | 20 | 28 | 28 | |
Highest | 1595 | (26) | 10 | 26 | 51 | |
Affiliation to the work market (age<65 years, n=3136) | ||||||
Working | 2240 | (71) | 56 | 72 | 83 | |
Unemployed/disability pensioner | 663 | (21) | 31 | 22 | 12 | |
Anticipatory pensioner | 235 | (8) | 13 | 6 | 5 | |
Charlson Comorbidity Index (n=6234) | ||||||
None | 4177 | (67) | 61 | 68 | 74 | <0.0001 |
1 | 1026 | (17) | 19 | 16 | 13 | |
2 | 595 | (10) | 11 | 9 | 10 | |
⩾3 | 436 | (7) | 9 | 7 | 4 | |
Year of diagnosis (n=6234) | ||||||
2000–2004 | 3234 | (52) | 55 | 51 | 50 | 0.0014 |
2005–2008 | 3000 | (48) | 45 | 49 | 51 | |
Ann Arbor stage (n=6051) | ||||||
1 | 1425 | (23) | 22 | 23 | 25 | 0.0021 |
2 | 715 | (12) | 11 | 12 | 12 | |
3 | 1021 | (16) | 16 | 18 | 15 | |
4 | 2890 | (46) | 48 | 46 | 46 | |
Two or more involved extranodal lesions (n=6234) | ||||||
No | 1076 | (17) | 19 | 17 | 17 | 0.2111 |
No | 5158 | (83) | 81 | 83 | 83 | |
Elevated level of LDH (n=5952) | ||||||
Yes | 2245 | (38) | 38 | 38 | 36 | 0.5926 |
No | 3707 | (62) | 62 | 62 | 64 | |
ECOG performance status (n=6169) | ||||||
0 | 3248 | (53) | 45 | 54 | 63 | <0.0001 |
1 | 1848 | (30) | 33 | 30 | 24 | |
2 | 539 | (9) | 12 | 8 | 5 | |
3 | 319 | (5) | 6 | 4 | 5 | |
4 | 215 | (4) | 5 | 3 | 3 | |
IPI score (n=5738) | ||||||
Low | 2124 | (37) | 29 | 40 | 44 | <.0001 |
Low–intermediate | 1816 | (32) | 33 | 31 | 31 | |
High–intermediate | 1129 | (20) | 22 | 19 | 17 | |
High | 669 | (12) | 16 | 10 | 9 | |
Histological subtype (n=6234) | ||||||
DLBCL | 2670 | (43) | 45 | 42 | 41 | 0.0005 |
LOW | 2490 | (40) | 37 | 41 | 43 | |
MCL | 341 | (6) | 6 | 5 | 5 | |
NHLNOS | 319 | (5) | 6 | 5 | 4 | |
PTCL | 414 | (7) | 6 | 7 | 7 | |
Chemotherapy (n=5025) | ||||||
Yes | 4297 | (86) | 86 | 85 | 84 | 0.36 |
No | 728 | (14) | 14 | 15 | 16 | |
Radiotherapy (n=4987) | ||||||
Yes | 1479 | (30) | 27 | 29 | 36 | <0.0001 |
No | 3508 | (70) | 73 | 71 | 64 | |
Immunotherapy (2005–2008, n=2187) | ||||||
Yes | 1111 | (51) | 47 | 53 | 50 | 0.11 |
No | 1076 | (49) | 53 | 47 | 50 | |
